$HCA

BMO Capital initiated coverage of HCA Healthcare (HCA) with an Outperform rating and $495 price target, citing investments in high-growth markets and efficiency gains. HCA reported Q2 2026 revenue of $20.230 billion, up 8.7% YoY, and Adjusted EBITDA of $4.027 billion, up 4.6%. Challenges include payer mix shifts and high debt. BMO expects 4-6% EBITDA CAGR despite macroeconomic pressures.

Analysts made several calls: UBS initiated CoreWeave as Buy with a $120 PT (~40% upside), KeyBanc initiated Guardian Pharmacy as Overweight, Wolfe raised Amazon's PT to $320, BMO initiated HCA Healthcare as Outperform, Morgan Stanley reiterated SpaceX as Overweight, Wells Fargo initiated Beta Bionics as Overweight with a $28 PT, Oppenheimer initiated Teva as Outperform with a $50 PT, Bernstein initiated Amphenol and TE Connectivity as Outperform, Rosenblatt reiterated Palantir as Buy, UBS…

BMO Capital initiated coverage on HCA Healthcare (NYSE:HCA) with an Outperform rating and $495 price target, citing growth drivers like demographic trends and digital transformation. HCA trades at $438.16 with $95.43B market cap, and reported Q2 2026 earnings beating estimates but lowered full-year guidance. Analysts have mixed reactions with varied price targets and ratings.

HCA Healthcare (HCA) anticipates $300M-$500M in state supplemental payments for 2026, offsetting exchange headwinds. Elective surgery volumes are pressured by patient migration to uninsured status, Medicare phaseouts, and economic conditions. The company targets 2%-3% long-term admission growth, investing in beds, outpatient facilities, and cost discipline. HCA expects to manage exchange pressures in 2027 and maintain 4%-6% revenue growth.

HCA Healthcare (HCA) completed its acquisition of The College of Health Care Professions (CHCP), expanding its healthcare education offerings. CHCP serves 8,000 students across 10 Texas campuses and online, with 20 accredited programs. HCA plans to integrate CHCP into its education and workforce development efforts. HCA stock is currently trading at $422.90, down 0.61%.

HCA Healthcare plans to invest over $32 million in facilities across western North Carolina. The initiative includes upgrades to Mission Hospital in Asheville. According to the company, the investment aims to enhance healthcare services in the region.

Kansas City hospitals report increased uninsured patients due to federal policy changes, including expired ACA premium tax credits and new Medicaid requirements. University Health lost $37.5M in revenue from uninsured patients, while HCA expects a $1B annual profit decline. KC Care anticipates $2M-$5M in revenue loss. Hospitals and clinics are taking steps to educate patients and mitigate coverage lapses.

Major for-profit health systems reported declines in surgical volumes in Q2 2026, citing insurance coverage reductions and consumer price consciousness. HCA, UHS, CHS, and Tenet Health all saw decreases, but executives remain optimistic about long-term demand. HCA's CEO noted potential easing of consumer sentiment in Q4. Companies are investing in outpatient capacity to meet future demand.

HCA Healthcare cut a small percentage of corporate and support roles, citing healthcare policy changes, rising costs, and more uninsured patients. The company lowered its 2026 revenue forecast to $77B-$79.5B and net income to $6.3B-$6.7B. Affected employees will receive severance and job placement support. HCA reported Q2 2026 operating income of $2.5B and a 12.3% margin.

HCA Healthcare (HCA) reduced its 2026 profit outlook, citing a weaker payer mix that decreased quarterly revenue by $400 million. A Pomerantz fraud investigation adds scrutiny. Shares fell 3.07% in 7 days, 2.02% in 30 days, despite a 12.09% gain in 90 days and 51.53% over 3 years. Analysts debate its valuation, with a fair value estimate of $458.67, above the recent $405.00 close.